北京大学学报(医学版) ›› 2017, Vol. 49 ›› Issue (4): 669-674. doi: 10.3969/j.issn.1671-167X.2017.04.022

• 论著 • 上一篇    下一篇

晚期结直肠癌患者一线应用FOLFOX方案化疗引起中性粒细胞减少的预后价值

陈杨,王艳荣,石燕,戴广海△   

  1. (中国人民解放军总医院肿瘤内二科, 北京, 100853)
  • 出版日期:2017-08-18 发布日期:2017-08-18
  • 通讯作者: 戴广海 E-mail: daigh60@sohu.com
  • 基金资助:
    吴阶平医学基金会临床科研专项基金(320.6750.11076)资助

Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX

CHEN Yang, WANG Yan-rong, SHI Yan, DAI Guang-hai△   

  1. (Medical Oncology of Department 2, Chinese PLA General Hospital, Beijing, 100853, China)
  • Online:2017-08-18 Published:2017-08-18
  • Contact: DAI Guang-hai E-mail: daigh60@sohu.com
  • Supported by:
    Supported by WU Jieping Medical Foundation for Clinical Research (320.6750.11076)

摘要: 目的:探讨一线应用奥沙利铂联合氟尿嘧啶、亚叶酸钙(FOLFOX)方案化疗的晚期结直肠癌患者中性粒细胞减少(chemotherapy-induced neutropenia,CIN)与预后的关系。方法: 回顾性分析一线应用FOLFOX方案化疗的晚期结直肠癌患者158例,根据患者化疗后3周期内最低中性粒细胞数与化疗前比较分为CIN程度大的组(较化疗前降低大于等于1.0×109)和程度小的组(较化疗前CIN降低小于1.0×109)以及无明显变化组,分析其与预后的关系。结果:CIN降低程度是患者预后指标无进展生存(progression free survival, PFS)和总生存(overall survival, OS)的独立影响因素。根据COX多因素回归分析,CIN程度大的组(large,L)较无明显变化组(absent,A)死亡风险降低31%(HR=0.687,95% CI: 0.381~0.812,P=0.016);CIN程度小的组(slight,S)较无明显变化组死亡风险降低18%(HR=0.817,95% CI: 0.527~0.939,P=0.027)。无明显变化组 (A)患者的中位OS为12.9个月,CIN程度少的组(S)患者的中位OS为17.3个月,CIN程度大的组(L)患者的中位OS为20.8个月(S vs. L, P=0.018; L vs. A, P=0.009; S vs. A, P=0.011)。结论:CIN程度是晚期结直肠癌化疗判断预后的独立影响因素,监测并根据CIN程度及时调整化疗药物剂量,或许有助于改善预后。

关键词: 结直肠肿瘤, 预后, 抗肿瘤联合化疗方案, 中性粒细胞减少

Abstract: Objective: To evaluate the prognostic value of chemotherapy-induced neutropenia (CIN) in metastatic colon cancer undergoing first-line chemotherapy with FOLFOX. Methods: Data were collected from a retrospective survey of 158 consecutive metastatic colon cancer patients who had undergone FOLFOX chemotherapy. The clinicopathological characteristics and chemotherapy features of the patients were analyzed as potential prognostic factors. The patients were stratified by the decreased level of CIN to three groups: large decreased level (the number of neutrophil decreased more than 1.0×109 compared with that before chemotherapy),small decreased level (the number of neutrophil decreased less than 1.0×109 compared with that before chemotherapy) and the absence of neutropenia. Results: According to a multivariate COX model, decreased level of CIN was a independent prognostic factor of colon cancer patients. Hazard ratios of death were 0.687 (95% CI: 0.381-0.812, P=0.016) for patients with large decreased level of CIN and 0.817 (95% CI: 0.527-0.939,P=0.027) for those with small decreased level of CIN compared with those of absent neutropenia patients. Median overall survival was 12.9 months (95% CI: 10.4-15.4) for patients without neutropenia (A) compared with 20.8 months (95% CI: 18.3-23.1) for patients with large-decreased level of CIN (L) and with 17.3 months (95% CI: 16.2-18.8) for those with small-decreased level of CIN (S vs. L, P=0.018; L vs. A, P=0.009; S vs. A, P=0.011). Conclusion: Our results demonstrate that the decreased level of CIN is a predictor of prognosis in patients with metastatic colon cancer undergoing FOLFOX chemotherapy. Patients who have experienced large decreased level of CIN haave longer survival time than small decreased level of CIN or absent patients. To monitor CIN decreased level timely and adjust chemotherapy drug dose may help improve the prognosis.

Key words: Colorectal neoplasms, Prognosis, Antineoplastic combined chemotherapy protocols, Neutropenia

中图分类号: 

  • R735.3
[1] 王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报(医学版), 2026, 58(2): 290-300.
[2] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[3] 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报(医学版), 2025, 57(6): 1067-1073.
[4] 郭博达, 陆敏, 王国良, 张洪宪, 刘磊, 侯小飞, 赵磊, 田晓军, 张树栋. 肾透明细胞癌与非透明细胞癌伴静脉癌栓患者的临床病理特征及预后比较[J]. 北京大学学报(医学版), 2025, 57(4): 644-649.
[5] 韩丹, 次仁央金, 李秋红, 李军. 高海拔地区结直肠良恶性肿瘤患者肠道菌群差异及其与低海拔地区正常人群的比较[J]. 北京大学学报(医学版), 2025, 57(3): 578-583.
[6] 李伟浩, 李晶, 张学民, 李伟, 李清乐, 张小明. 术中回收式自体输血对颈动脉体瘤切除术后肿瘤预后的影响[J]. 北京大学学报(医学版), 2025, 57(2): 272-276.
[7] 毛雅晴, 陈震, 于尧, 章文博, 刘洋, 彭歆. 2型糖尿病对口腔鳞状细胞癌患者预后的影响[J]. 北京大学学报(医学版), 2024, 56(6): 1089-1096.
[8] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[9] 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报(医学版), 2024, 56(4): 624-630.
[10] 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报(医学版), 2024, 56(4): 661-666.
[11] 周泽臻,邓绍晖,颜野,张帆,郝一昌,葛力源,张洪宪,王国良,张树栋. 非转移性T3a肾细胞癌患者3年肿瘤特异性生存期预测[J]. 北京大学学报(医学版), 2024, 56(4): 673-679.
[12] 方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报(医学版), 2024, 56(4): 741-744.
[13] 曾媛媛,谢云,陈道南,王瑞兰. 脓毒症患者发生正常甲状腺性病态综合征的相关因素[J]. 北京大学学报(医学版), 2024, 56(3): 526-532.
[14] 苏俊琪,王晓颖,孙志强. 舌鳞状细胞癌根治性切除术后患者预后预测列线图的构建与验证[J]. 北京大学学报(医学版), 2024, 56(1): 120-130.
[15] 李建斌,吕梦娜,池强,彭一琳,刘鹏程,吴锐. 干燥综合征患者发生重症新型冠状病毒肺炎的早期预测[J]. 北京大学学报(医学版), 2023, 55(6): 1007-1012.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!